An update on Patrys has been published in the latest issue of investor newsletter Bioshares this week.
Titled ‘Patrys Demonstrates Success with PAT-DX3 Drug Conjugate’ the article highlights the promising results from our preclinical study showing the potential of PAT-DX3 as a targeting agent for antibody drug conjugates.